Cipla gets nod for generic version of Shire’s Firazyr

Pharma major Cipla has announced that the company has received the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.The purpose of the Icatibant injection is for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.


Please enter your comment!
Please enter your name here